RSLS - ReShape Lifesciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2597
0.0000 (0.00%)
At close: 2:49PM EDT
Stock chart is not supported by your current browser
Previous Close0.2597
Open0.0725
Bid0.0000 x 1100
Ask0.0000 x 3000
Day's Range0.0528 - 0.0598
52 Week Range0.0400 - 8.4000
Volume186,243
Avg. Volume219,945
Market Cap7.948M
Beta (3Y Monthly)2.50
PE Ratio (TTM)N/A
EPS (TTM)-8.5430
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Trade prices are not sourced from all markets
  • ACCESSWIRE

    ReShape Lifesciences(TM) to Participate in the H. C. Wainwright Global Investment Conference

    SAN CLEMENTE, CA / ACCESSWIRE / September 3, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the ...

  • ACCESSWIRE

    ReShape Lifesciences(TM) to Highlight Products at IFSO 24th World Congress

    SAN CLEMENTE, CA / ACCESSWIRE / August 22, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRE

    ReShape Lifesciences to Host Second Quarter 2019 Conference Call on August 14, 2019

    SAN CLEMENTE, CA / ACCESSWIRE / August 8, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that ...

  • ACCESSWIRE

    ReShape Lifesciences Announces CFO Resignation

    SAN CLEMENTE, CA / ACCESSWIRE / August 6, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today Scott Youngstrom will resign as Chief Financial Officer effective October 1, 2019, per his retention agreement. "We greatly appreciate the contributions Scott has made during his tenure at ReShape Lifesciences," stated Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences. Scott Youngstrom, Chief Financial Officer of ReShape Lifesciences stated, "It is with mixed emotions that I announce my departure from ReShape.

  • ACCESSWIRE

    ReShape Lifesciences to Highlight LAP-Band Weight Loss Technology at ASMBS Spring Meeting

    SAN CLEMENTE, CA / ACCESSWIRE / June 18, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRE

    ReShape Lifesciences Announces $8 Million Private Placement

    SAN CLEMENTE, CA / ACCESSWIRE / June 14, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with certain healthcare focused institutional investors for the sale of 400,000,000 shares of common stock (or common stock equivalents), series A warrants to purchase up to 400,000,000 shares of common stock and series B warrants to purchase up to 400,000,000 shares of common stock in a private placement at a price of $0.02 per share and associated warrants for gross proceeds of approximately $8 million. The number of shares of common stock (and common stock equivalents) issuable to the investors is subject to adjustment following the effectuation of a reverse stock split by the Company, as set forth in the definitive agreements.

  • ACCESSWIRE

    ReShape Lifesciences Strengthens Executive Leadership Team with Appointment of Kevin Condrin as Senior Vice President of Commercial

    SAN CLEMENTE, CA / ACCESSWIRE / June 4, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment ...

  • ACCESSWIRE

    ReShape Lifesciences Announces First Quarter 2019 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / May 20, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • ACCESSWIRE

    ReShape Lifesciences to Host First Quarter 2019 Conference Call on May 20, 2019

    SAN CLEMENTE, CA / ACCESSWIRE / May 20, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it ...

  • ACCESSWIRE

    ReShape Lifesciences Announces Distribution in Australia

    SAN CLEMENTE, CA / ACCESSWIRE / April 18, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that as of April 1, 2019, the company is selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market. The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND® while it was owned by Allergan and Apollo Endosurgery respectively.

  • ACCESSWIRE

    ReShape Lifesciences Announces Fourth Quarter and Full Year 2018 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months and year ended December 31, 2018. Reported gross margins from continuing operations of 73% for the full year 2018.

  • ACCESSWIRE

    ReShape Lifesciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences, Inc. (OTCQB: RSLS ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 1, 2019 at 4:30 ...

  • ACCESSWIRE

    ReShape Lifesciences Implants First Patient in ENDURE II Trial to Support CE Marking of ReShape Vest

    SAN CLEMENTE, CA / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company has successfully implanted its first patient in the ENDURE II trial designed to support CE Marking of the ReShape VestTM. The ReShape Vest is a minimally invasive non-anatomy changing obesity solution that restricts stomach volume without cutting, stapling, or removing the stomach. In a pilot study of 17 patients who were implanted with the ReShape Vest, early clinical results showed 85% excess weight loss at one year.

  • ACCESSWIRE

    ReShape Lifesciences Announces $2 Million Convertible Note Financing

    SAN CLEMENTE, CA / ACCESSWIRE / March 29, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into a definitive agreement with certain institutional investors for a $2 million convertible note financing, which notes will be issued in a private placement. The notes will mature three months after their issuance and, if not repaid, will then initially be convertible into shares of common stock at a conversion price equal to the lesser of $0.33 and 80% of the average of the lowest two volume weighted average prices of the company's common stock during the 20 trading days prior to conversion. In connection with the financing, the company will amend the exercise price of warrants to purchase up to 8 million shares of common stock held by the investors that were issued on November 28, 2018 from $1.50 per share to $0.01 per share.

  • ACCESSWIRE

    ReShape Lifesciences Announces Appointment of Barton P. Bandy as President and Chief Executive Officer

    SAN CLEMENTE, CA / ACCESSWIRE / March 26, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Barton P. Bandy as President and Chief Executive Officer effective April 1, 2019. As previously announced, Dan W. Gladney will step down as President and Chief Executive Officer on March 31, 2019 and will continue to serve as Chairman of the Board for ReShape Lifesciences.

  • ACCESSWIRE

    ReShape Lifesciences to Host Fourth Quarter and Full Year 2018 Conference Call on April 1, 2019

    SAN CLEMENTE, CA / ACCESSWIRE / March 19, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that ...

  • ACCESSWIRE

    ReShape Vest to be Showcased at 4th Annual Surgical Disruptive Technology Summit

    SAN CLEMENTE, CA / ACCESSWIRE / February 25, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company's ReShape VestTM will be discussed during a session at the 4th Annual Surgical Disruptive Technology Summit taking place at the JW Marriott Hotel in Houston, Texas from March 2-4, 2019. The Surgical Disruptive Technology Summit, which is hosted by the Department of Surgery at the University of Texas Health Science Center at Houston and the McGovern Medical School, is the pre-eminent educational forum for General, Bariatric, Colorectal, and Oncological Surgeons.

  • ACCESSWIRE

    ReShape Lifesciences to Debut LAP-BAND Technology at Minimally Invasive Surgery Symposium

    SAN CLEMENTE, CA / ACCESSWIRE / February 19, 2019 / ReShape Lifesciences Inc. (OTC PINK: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today ...

  • ACCESSWIRE

    ReShape Lifesciences Announces Chief Executive Officer Departure

    SAN CLEMENTE, CA / ACCESSWIRE / January 28, 2019 / ReShape Lifesciences Inc. (OTC Pink: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that Dan W. Gladney has decided to step down from his role as President and Chief Executive Officer of the company effective as of March 31, 2019. The ReShape Lifesciences Board of Directors will immediately begin to search for the company's next President and Chief Executive Officer. ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases.

  • ACCESSWIRE

    Small Cap Biotech Stocks on the Rise

    HENDERSON, NV / ACCESSWIRE / December 28, 2018 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price ...

  • Business Wire

    Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc. (“ReShape”) (RSLS). The definitive transaction agreements were signed and closed simultaneously yesterday, December 17, 2018. This transaction will allow Apollo to focus all its efforts on growing the clinical adoption of its Endo-bariatric product offerings, which consists of its OverStitch Endoscopic Suturing Systems and the Orbera Intragastric Balloon technologies.

  • ACCESSWIRE

    ReShape Lifesciences Acquires Lap-Band System in Exchange for ReShape Balloon

    SAN CLEMENTE, CA / ACCESSWIRE / December 18, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that it has acquired the Lap-Band® adjustable gastric band system from Apollo Endosurgery, Inc. and that Apollo Endosurgery has acquired the ReShape Balloon™ product line from ReShape Lifesciences. ReShape Lifesciences will pay Apollo Endosurgery a total cash purchase price of $17 million, with $10.0 million dollars paid at closing and the additional $7.0 million dollars to be paid in three annual installments beginning on the first anniversary of the closing of the transaction.

  • ACCESSWIRE

    ReShape Lifesciences Expands International Business in the Middle East

    In January 2019, Dr. Haya Ahmed Khalfan Isa Khalfan, Consultant General Surgeon at BDF Military Hospital in Bahrain will be trained at a facility in the United States on using the ReShape Balloon. Dr. Khalfan will be the first surgeon in Bahrain to be trained on the ReShape Balloon.

  • ACCESSWIRE

    ReShape Lifesciences Announces Live Surgery Course for ReShape Vest

    SAN CLEMENTE, CA / ACCESSWIRE / December 3, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the Company will be holding a live-surgery surgical training for bariatric surgeons and key opinion leaders who will serve as investigators in the Company's ENDURE II trial in the European Union. The training will occur on February 4-5, 2019, in Prague, Czech Republic and is designed to provide practical experience to support initiation of the Company's ENDURE II trial in early Q1 2019. The ReShape Lifesciences ENDURE II trial is an investigative, prospective, non-randomized, multi-center study to assess the safety and effectiveness of the Reshape Vest for treatment of obese patients.

  • ACCESSWIRE

    ReShape Lifesciences Provides Financing and Corporate Update

    As a result of the aggregate $25 million in gross proceeds raised in these recent financings and the Company's continued efforts to manage its expenses, the Company believes that it should have sufficient capital to fund its current operations into 2020. "We are really pleased with the progress we have made in getting our capital structure back to health," said Dan Gladney, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences.